Bristol-Myers Buys Amylin for $5.3B, Strikes Alliance with AstraZeneca

By Jennifer Booton Features FOXBusiness

Bristol-Myers Squibb (BMY) said it is buying smaller rival and diabetes-focused Amylin (AMLN) for about $5.3 billion.

Continue Reading Below

Shares of Amylin soared nearly 9% to multi-year highs on Monday, while Bristol-Myers climbed 1% to a 10-year high.

The deal calls for Bristol-Myers to buy San Diego, Calif.-based Amylin for $31 a share. Including Amylin’s debt, the total value of the transaction is $7 billion. The shares will be acquired through a tender offer, following which the companies will undergo a second-step merger.  

The deal gives Bristol-Myers a robust pipeline of type-2 diabetes drugs, including Amylin's novel GLP-1 franchise that houses Byetta and Bydureon, which is the first ever once-weekly therapy for type 2 diabetes patients.

The announcement comes less than a week after the U.S. Supreme Court upheld President Barack Obama’s health-care law that is expected to make it easier for people with pre-existing conditions like diabetes to access insurance.

Bristol-Myers also said it has inked a deal with AstraZeneca (AZN) building off their existing diabetes alliances that calls for the joint development and commercialization of Amylin’s products.

Continue Reading Below

Under the terms of that deal, AstraZeneca will make a $3.4 billion cash payment to Amylin, which will be a wholly-owned subsidiary of Bristol-Myers. If AstraZeneca chooses to pay another $135 million, it will be able to establish equal governance rights over key strategic and financial decisions over Amylin, Bristol said in a statement.

The agreements have been approved by the boards of directors of all three drug companies.

AstraZeneca said its deal with Bristol-Myers will have “an immediate positive impact on revenues,” and is in line with its strategic to enhance top-line growth and strengthen its late-stage pipeline.

“Amylin’s innovative diabetes portfolio, talented people and state-of-the art manufacturing facility complement our long-standing leadership in metabolics,” Bristol-Myers CEO Lamberto Andreotti said in a statement.